This study was performed to determine the prevalence of anti-agalactosyl IgG antibodies in Thai patients with RA, systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), and determine the sensitivity and specificity of anti-agalactosyl IgG antibodies in the diagnosis of RA in comparison with IgM-rheumatoid factor (IgM-RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Serum samples were obtained from 100 patients with RA, 50 cases of SLE, 50 cases of SSc, and 100 healthy controls and analyzed for the presence of anti-agalactosyl IgG antibodies, IgM-RF and anti-CCP antibodies. A serum value greater than mean + 2 standard deviation of normal value of anti-agalactosyl IgG antibodies and anti-CCP antibodies was considered positive. The prevalence of anti-agalactosyl IgG antibodies in RA, SLE, and SSc patients was 88.0%, 14.0%, and 12.0%, respectively. The serum level of anti-agalactosyl IgG antibodies in patients with RA (227.10 ± 353.64 AU/mL) was significantly higher than those in SLE (11.84 ± 52.04 AU/mL), SSc (18.85 ± 99.60 AU/mL), and healthy controls (2.14 ± 1.97 AU/mL), (p < 0.001). There was a good correlation between the log serum level of anti-agalactosyl IgG antibodies and IgM-RF (r = 0.92, p < 0.001), anti-CCP antibodies and IgM-RF (r = 0.49, p < 0.001), and anti-agalactosyl IgG antibodies and anti-CCP antibodies (r = 0.55, p < 0.001). The sensitivity and specificity in the diagnosis of RA was 88.00% and 96.00% for anti-agalactosyl IgG antibodies, 90.00% and 99.00% for anti-CCP antibodies, and 91.00% and 95.00% for IgM-RF, respectively. The serum level of anti-agalactosyl IgG antibodies was significantly higher in RA than in SLE, SSc, and healthy controls. There was a good correlation between serum levels of anti-agalactosyl IgG antibodies, anti-CCP antibodies, and IgM-RF. These three tests had comparable sensitivity and specificity.
This is a preview of subscription content, log in to check access.
This study was partially supported by a grant from the Ministry of Education, Culture, Sport, Science and Technology of Japan, and the Faculty of Medicine, Chiang Mai University Endowment Fund.
Worawit Louthrenoo, M.D.—Received a grant from the Faculty of Medicine, Chiang Mai University.
Nuntana Kasitanon, M.D.—None.
Ramjai Wichainun, B.Sc.—None.
Suparaporn Wangkaew, M.D.—None.
Waraporn Sukitawut, B.Sc.—None.
Shoji Kuwata, M.D.—None.
Fujio Takeuchi, M.D.—Received a grant from the Ministry of Education, Culture, Sport, Science and Technology of Japan.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMedGoogle Scholar
Tighe H, Carson DA (2005) Rheumatoid factor. In: Harris ED, Budd RC, Firestein GS et al (eds) Kelley's textbook of rheumatology. Philadelphia, Elsevier Saunders, pp 301–310Google Scholar
Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 42:677–680CrossRefGoogle Scholar
Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65:845–851CrossRefPubMedGoogle Scholar
Matsui T, Shimada K, Ozawa N, Hayakawa H, Hagiwara F, Nakayama H et al (2006) Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol 33:2390–2397PubMedGoogle Scholar
Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835CrossRefPubMedGoogle Scholar
Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, van der Stadt RJ, de Koning MH, Dijkmans BA (2003) The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 30:1691–1695PubMedGoogle Scholar
Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095CrossRefPubMedGoogle Scholar
Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P et al (2008) High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 67:212–217CrossRefPubMedGoogle Scholar
Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D et al (1985) Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316:452–457CrossRefPubMedGoogle Scholar
Watson M, Rudd PM, Bland M, Dwek RA, Axford JS (1995) Sugar printing rheumatic diseases: a potential method for disease differentiation using immunoglobulin G oligosaccharides. Arthritis Rheum 42:1682–1690CrossRefGoogle Scholar
Imafuku Y, Yoshida H, Yamada Y (2003) Reactivity of agalactosyl IgG with rheumatoid factor. Clin Chim Acta 334:217–223CrossRefPubMedGoogle Scholar
Matsumoto A, Shikata K, Takeuchi F, Kojima N, Mizuochi T (2000) Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation. J Biochem 128:621–628PubMedGoogle Scholar
Das H, Atsumi T, Fukushima Y, Shibuya H, Ito K, Yamada Y et al (2004) Diagnostic value of antiagalactosyl IgG antibodies in rheumatoid arthritis. Clin Rheumatol 23:218–222CrossRefPubMedGoogle Scholar
Kondo S, Mashima T, Kai M, Yamada Y, Yoshizawa M, Hosoda T (1997) The study of serum antiagalactosyl IgG antibody in early rheumatoid arthritis. Rinshou Kenkyu 31:190–194Google Scholar
Lacki JK, Porawska W, Mackiewicz U, Mackiewicz S, Muller W (1996) Changes in agalactosyl IgG levels correlate with radiological progression in early rheumatoid arthritis. Ann Med 28:265–269CrossRefPubMedGoogle Scholar
van Zeben D, Rook GA, Hazes JM, Zwinderman AH, Zhang Y, Ghelani S et al (1994) Early agalactosylation of IgG is associated with a more progressive disease course in patients with rheumatoid arthritis: results of a follow-up study. Br J Rheumatol 33:36–43CrossRefPubMedGoogle Scholar
Lu MC, Hsieh SC, Lai NS, Li KJ, Wu CH, Yu CL (2007) Comparison of anti-agalactosyl IgG antibodies, rheumatoid factors, and anti-cyclic citrullinated peptide antibodies in the differential diagnosis of rheumatoid arthritis and its mimics. Clin Exp Rheumatol 25:716–721PubMedGoogle Scholar
Mimra Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N et al (2005) Anti-agalactosyl immunoglobulin G antibodies in localized scleroderma. Int J Dermatol 44:817–820CrossRefPubMedGoogle Scholar
Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N et al (2004) Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis. Br J Dermatol 151:803–808CrossRefPubMedGoogle Scholar
Nishijima C, Sato S, Takehara K (2001) Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis. J Rheumatol 28:1847–1851PubMedGoogle Scholar
Leirisalo-Repo M, Hernandez-Munoz HE, Rook GA (1999) Agalactosyl IgG is elevated in patients with active spondyloarthropathy. Rheumatol Int 18:171–176CrossRefPubMedGoogle Scholar
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMedGoogle Scholar
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMedGoogle Scholar
Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRefGoogle Scholar
Kudo-Tanaka E, Ohshima S, Ishii M, Mima T, Matsushita M, Azuma N et al (2007) Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol 26:1627–1633CrossRefPubMedGoogle Scholar
Ichikawa Y, Yamada C, Horiki T, Hoshina Y, Uchiyama M, Yamada Y et al (1998) Anti-agalactosyl IgG antibodies and isotype profiles of rheumatoid factors in Sjogren's syndrome and rheumatoid arthritis. Clin Exp Rheumatol 16:709–715PubMedGoogle Scholar
Ezaki I, Shingu M, Furuta E (1995) Clinical significance of anti-agalactosyl IgG antibody in early rheumatoid arthritis. Kiso Rinsho 30:3599–3606Google Scholar
Maeno N, Takei S, Fujikawa S, Yamada Y, Imanaka H, Hokonohara M et al (2004) Antiagalactosyl IgG antibodies in juvenile idiopathic arthritis, juvenile onset Sjogren's syndrome, and healthy children. J Rheumatol 31:1211–1217PubMedGoogle Scholar
Chan MT, Owen P, Dunphy J, Cox B, Carmichael C, Korendowych E et al (2008) Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol 35:77–83PubMedGoogle Scholar
Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, Tak PP (2004) The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 50:3485–3494CrossRefPubMedGoogle Scholar
Matsui T, Shimada K, Tohma S (2006) Anti-cyclic citrullinated peptide antibody in rheumatic diseases other than rheumatoid arthritis. Clin Rheumatol 25:610–611CrossRefPubMedGoogle Scholar